联合治疗 UTHR 深 沪
已收盘 02-06 16:00:00 美东时间
485.36
+6.430
+1.34%
华盛通- 最 高489.50
- 今 开483.81
- 成交量 29.72万股
- 最 低 481.95
- 昨 收 478.93
- 总市值 208.98亿
- 52周最高 519.99
- 市盈率 静 19.70
- 换手率 0.69%
- 52周最低 266.98
- 委 比 -55.17%
- 总股本 4305.66万
- 历史最高 519.99
- 量 比 0.77
- 振 幅 1.58%
- 历史最低 36.55
- 每 手 1
- 风险率 79.06%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多United Therapeutics Director Jan Malcolm Reports Sale of Common Shares
United Therapeutics Director Jan Malcolm Reports Sale of Common Shares Jan Malcolm, Director of United Therapeutics Corporation, reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies
02-04 05:32
United Therapeutics Reports Early Success For External Liver Support In Acute Failure
United Therapeutics' external liver assist product shows positive results in phase 1 study for acute liver failure patients.
01-26 21:55
BRIEF-United Therapeutics Announces Positive Results From Phase 1 Study Of Miroliverelap In Patients With Acute Liver Failure
BRIEF-United Therapeutics Announces Positive Results From Phase 1 Study Of Miroliverelap In Patients With Acute Liver Failure Jan 26 (Reuters) - United Therapeutics Corp UTHR.O : UNITED THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM PHASE 1 STUDY OF MIROLIVERELAP® IN PATIENTS WITH ACUTE LIVER FAILURE
01-26 20:02
United Therapeutics appoints new director, updates bylaws
United Therapeutics ( ($UTHR) ) has issued an update. On January 21, 2026, Unit...
01-23 06:26
United Therapeutics Appoints Kevin J. Tracey to Board of Directors
United Therapeutics Appoints Kevin J. Tracey to Board of Directors United Therapeutics Corporation has appointed Kevin J. Tracey, M.D., to its Board of Directors, effective January 21, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligenc
01-22 20:01
美股大行评级 | 拼多多、小鹏获Freedom上调目标价；多家大行首予Wealthfront"超配"评级，目标价最高23美元
今日重点评级关注：HC Wainwright & Co.：维持MetaVia Inc."买入"评级，目标价从12美元升至40美元；Canaccord Genuity：维持GH Research"买入"评级，目标价从35美元升至39美元
01-07 17:25
UBS Maintains Buy on United Therapeutics, Raises Price Target to $645
UBS analyst Ashwani Verma maintains United Therapeutics (NASDAQ:UTHR) with a Buy and raises the price target from $600 to $645.
01-07 01:53
美股盘后 | JBS N.V. Class A涨2.86%，百胜餐饮涨2.48%
JBS N.V. Class A涨2.86%；百胜餐饮涨2.48%；Silver Wheaton Corp.涨1.99%
2025-12-17 07:11
